Your Cart is Empty
LDN 2023 Recorded Presentations
| LDN in Dermatology | April Bodemer, MD, FAAD |
| LDN for Chronic Pain in Hypermobility Spectrum Disorder / Ehlers-Danlos Syndrome | Lynn Gufeld, AGACNP |
| Low Dose Naltrexone | Darin Ingels, ND |
| Long COVID: Pathogenesis, and Treatment Options, Including Low Dose Naltrexone | John Lambert, MD, PhD |
|
1. LDN for Alcohol Use Disorder 2. LDN Surprises and Side Effects" |
Elizabeth Livengood, ND |
| Advances in Dosing of LDN, Note from a Compounding Pharmacist | Michelle Moser, RPh, FACA, FACVP |
| New Concepts in the Treatment of PCOS | Pamela Smith, MD, MPH, MS |
| Low Dose Naltrexone as an Adjunctive Therapy for Speech Acquisition in Autism Spectrum Disorder | Brian D Udell, MD |
| LDN, Peptides and Synergistic Therapies to Support Immune Tolerance | Cory Tichauer, ND |
| The Applications of Different LDN Dosage Forms that Compounding Pharmacists Offer (Lozengez, Capsule, Topical, Suspension); Pet and Human Dosages | Masoud Rashidi, PharmD |
|
Lowering Hashimoto's Thyroiditis Antibodies with LDN Mona Morstein, ND, DHANP, VNMI LDN and Alopecia |
Miriam Martinez Callejas, MPharm |
| Scar and Wound Therapy with Topical LDN | Nat Jones RPh, FAPC |
| LDN Reduced Anxiety in PwMS During the COVID-19 Pandemic | Laura Odom, Anatomy Ph.D. Candidate |
| Dosing Variability and Clinic Perspective | Sebastian Denison Clinical Compounding Pharmacist |
| LDN & Emergent Immune Events | Stefanie Werner, NMD |
| An Introduction to Blockages | Richard Nahas, MD |
|
1. Cancer and Case Studies 2. Long COVID and Case Studies |
Angus Dalgleish, MD, FRCP, FRACP |
| Hopkins Long COVID Clinic Experience with LDN | Alba Miranda Azola, MD |
| Complex Regional Pain Syndrome | Samyadev Datta, MD |